[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.167.137. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
October 4, 2000

The Role of Genotypic Resistance Testing in Selecting Therapy for HIV—Reply

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor

JAMA. 2000;284(13):1649-1650. doi:10.1001/jama.284.13.1647

In Reply: We have previously addressed the issues raised by Drs Pèrez-Molina and Fernández.1 As we have stated, resistance testing (genotypic as well as phenotypic) should be viewed in the context of many other factors when choosing drug therapy. Such factors include treatment history, viral load, medication tolerance, adherence, and concomitant medical conditions. Pèrez-Molina and Fernández raise a theoretical concern regarding linkage of mutations that we have discussed previously1 and that may apply to phenotyping as well as genotyping.

First Page Preview View Large
First page PDF preview
First page PDF preview
×